Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505375 · ClinicalTrials.gov registry record · Phase 2
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00505375 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 112 participants.
The verdict
NCT00505375, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
Interventions
- OTHER Placebo
- DRUG CTLA-4 Ig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505375
The ClinicalTrials.gov registry entry for NCT00505375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00505375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505375 about?
NCT00505375 is a clinical study titled "Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus". The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in individuals with new onset T1DM will improve insulin secretion (C-peptide production) compared to placebo.
What is the current status of trial NCT00505375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2008-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00505375?
The interventions under investigation include: Placebo (OTHER), CTLA-4 Ig (DRUG).
Who is sponsoring clinical trial NCT00505375?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.